Krystal Biotech Inc Quick Ratio (KRYS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Krystal Biotech Inc   (NASDAQ: KRYS)

Krystal Biotech Inc 's Quick Ratio

KRYS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 6.64 below Krystal Biotech Inc average.

Within Biotechnology & Pharmaceuticals industry 53 other companies have achieved higher Quick Ratio than Krystal Biotech Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 608, from total ranking in the first quarter 2026 at 748.

Explain Quick Ratio?
How much Cash & cash equivalents KRYS´s has?
What are KRYS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KRYS Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 46.61 % 35.62 % 11.63 % 1.94 % 20.94 %
Y / Y Cash & cash equivalent Change 23.99 % 33.49 % 38.54 % 24.26 % 21.87 %
Quick Ratio MRQ 6.64 7.64 7.27 8.01 7.85
KRYS's Total Ranking # 608 # 748 # 627 # 645 # 678
Seq. Current Liabilities Change 18.18 % -5.32 % 24.75 % 5.03 % 9.32 %
Seq. Cash & cash equivalent Change 2.7 % -0.53 % 13.23 % 7.2 % 10.56 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 54
Healthcare Sector # 244
Overall Market # 661


Quick Ratio Statistics
High Average Low
126.96 32.93 5.86
(Jun 30 2018)   (Dec 31 2024)




Financial Statements
Krystal Biotech Inc 's Current Liabilities $ 127 Millions Visit KRYS's Balance sheet
Krystal Biotech Inc 's Cash & cash equivalent $ 846 Millions Visit KRYS's Balance sheet
Source of KRYS's Sales Visit KRYS's Sales by Geography


Cumulative Krystal Biotech Inc 's Quick Ratio

KRYS's Quick Ratio for the trailling 12 Months

KRYS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 23.03 % 16.61 % 19.47 % 48.58 % 98.71 %
Y / Y Cash & cash equivalent TTM Growth 29.91 % 29.71 % 25.13 % 18.44 % 13.35 %
Quick Ratio TTM 7.33 7.66 7.69 7.31 6.94
Total Ranking TTM # 340 # 404 # 292 # 297 # 300
Seq. Current Liabilities TTM Growth 10.13 % 7.62 % 3.3 % 0.49 % 4.39 %
Seq. Cash & cash equivalent TTM Growth 5.34 % 7.23 % 8.76 % 5.75 % 5.18 %

Quick ratio ranking by company, industry and sector >> Back to KRYS Financial Strength Comparisons >> Go to Compare KRYS Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $127.40 millions, cumulative Quick Ratio decreased to 7.33 below the Krystal Biotech Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Krystal Biotech Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2600.

Explain Quick Ratio?
How much Cash & cash equivalents KRYS´s has?
What are KRYS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 139
Healthcare Sector # 858
Within the Market # 608


trailing twelve months Quick Ratio Statistics
High Average Low
50.41 19.28 2.89
(Jun 30 2020)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Relay Therapeutics Inc   17.93 $ 910.934  Millions$ 50.804  Millions
Maze Therapeutics Inc   17.90 $ 411.087  Millions$ 22.961  Millions
Crispr Therapeutics Ag  17.79 $ 2,364.352  Millions$ 132.896  Millions
Taysha Gene Therapies Inc   17.53 $ 455.407  Millions$ 25.975  Millions
Aura Biosciences Inc   16.56 $ 323.840  Millions$ 19.560  Millions
Kalaris Therapeutics Inc   16.46 $ 143.865  Millions$ 8.738  Millions
Kyverna Therapeutics Inc   16.10 $ 367.021  Millions$ 22.802  Millions
Tectonic Therapeutic Inc   15.96 $ 227.068  Millions$ 14.224  Millions
Candel Therapeutics Inc   15.89 $ 201.565  Millions$ 12.685  Millions
Inhibikase Therapeutics Inc   15.50 $ 159.019  Millions$ 10.260  Millions
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions
Odyssey Therapeutics, Inc.  10.98 $ 310.575  Millions$ 28.295  Millions
Protara Therapeutics Inc  10.70 $ 142.494  Millions$ 13.319  Millions
Engene Therapeutics Inc   9.79 $ 266.320  Millions$ 27.209  Millions
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions
Redwoods Acquisition Corp  7.69 $ 9.300  Millions$ 1.210  Millions
Cardiff Oncology Inc   7.04 $ 76.005  Millions$ 10.797  Millions

Date modified: 2026-09-12T18:37:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.